Abstract:Su Zhang, 1 Ke Xu, 2 Su-Xiao Liu, 3 Xiao-Lan Ye, 1 Ping Huang, 1 Hong-Juan Jiang 1 1 Center for Clinical Pharmacy, Cancer Center, Department of Pharmacy, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, People's Republic of China; 2 Laboratory Medicine Center, Department of Clinical Laboratory, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, People's Republic of China; 3 Center for Reproductive Medicine, Department of Obstetrics, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, People's Republic of China Correspondence: Hong-Juan Jiang, Center for Clinical Pharmacy, Cancer Center, Department of Pharmacy, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, People's Republic of China, Tel +86 571 85893143, Fax +86 571 87666666, Email Purpose: Ureaplasma urealyticum and Mycoplasma hominis began to show resistance to azithromycin, a macrolide antibiotic commonly used in pregnancy. Unfortunately, there are few effective and safe drugs in the clinic for genital mycoplasmas in pregnant women. In the present study, we investigated the prevalence of azithromycin-resistant U. urealyticum and M. hominis infections in pregnant women. The secondary research objects were possible influencing factors and consequences of insensitive Mycoplasma infection. Patients and methods: A retrospective analysis was carried out in pregnant women who underwent cervical Mycoplasma culture between October 2020 and October 2021 at a large general hospital in eastern China. The sociological characteristics and clinical information of these women were collected and analyzed. Results: A total of 375 pregnant women were enrolled, and 402 cultured mycoplasma specimens were collected. Overall, 186 (49.60%) patients tested positive cervical Mycoplasma infection, and 37 (9.87%) had infections caused by azithromycin-resistant Mycoplasma. In total, 39 mycoplasma samples were insensitive to azithromycin in vitro, also showing extremely high resistance to erythromycin, roxithromycin, and clarithromycin. Azithromycin was the only antibiotic used in women with Mycoplasma cervical infection, regardless of azithromycin resistance in vitro. Statistical results showed that azithromycin-resistant cervical Mycoplasma infection in pregnant women was unrelated to age, body mass index (BMI), gestational age, number of embryos, and assisted reproductive technology (ART) use, but led to a significantly increased incidence of adverse pregnancy outcomes (spontaneous abortion (SA), preterm birth (PTB), preterm prelabor rupture of membranes (PPROM), and stillbirth). Conclusion: Azithromycin-resistant U. urealyticum and M. hominis cervical infections are relatively common during pregnancy, and can increase the risk of adverse pregnancy outcomes; however, there is currently a lack of safe and effective drug treatments. Herein, we show that azithromycin-resistant mycoplasma infection requires timely intervention. Keywords: azithromycin resistance, Ureaplasma urealyticum , Mycoplasma hominis , pregnant women Mycoplasma are a form of small, free-living microorganism. 1 The mycoplasma species Ureaplasma urealyticum, Mycoplasma hominis, Ureaplasma parvum , and Mycoplasma genitalium are the most common mycoplasma associated with urogenital tract infections. 1 These microbes, particularly U. urealyticum , commonly colonize the urogenital tract without causing symptoms or harmful effects in nonpregnant women. 2,3 However, several studies have reported that post-pregnancy mycoplasma infection in the genital tract is associated with adverse pregnancy outcomes, including preterm birth (PTB), preterm prelabor rupture of membranes (PPROM), low birth weight (LBW), spontaneous abortion (SA), and stillbirth. 4–6 Other studies have suggested that, in conjunction with bacterial vaginosis (BV), mycoplasma infection plays a role in causing adverse pregnancy outcomes. 7,8 M. hominis infection was identified as a potential risk factor for SA, stillbirth, and PPROM in a meta-analysis in 2021. 9 However, the latest meta-analysis data shows that the currently available literature does not allow conclusions about the role of mycoplasmas in adverse pregnancy outcomes, alone or coexisting with BV due to strong data bias. 10 Nevertheless, the clinical consensus is that gestational women with sym -Abstract Truncated-

A Prospective Study on Relationship Between Genital Tract Mycoplasma Infection in Pregnant Women and Adverse Perinatal Outcomes

Correlation Between Ureaplasma Spp. Sub-Group 1 and Preterm Pre-Labour Rupture of Membranes Revealed by an Emlst Scheme

The Relation Between Neonates Pneuminia and Mycoplasma Pcoplasma Infection of Maternity

Adverse pregnancy outcomes among women with syphilis in Zhejiang province, 2013-2014

The Relationship Between Vaginal Flora at Late Pregnancy and Pregnancy Outcomes

The relationship between mycoplasma infection in different parts of male genitourinary tract and infertility

Detection and analysis of pathogens for preterm premature rupture of membranes

Adverse pregnancy and birth outcomes associated with Mycoplasma hominis, Ureaplasma urealyticum and Ureaplasma parvum: a systematic review and meta-analysis

Co-infection with vaginal Ureaplasma urealyticum and Mycoplasma hominis increases adverse pregnancy outcomes in patients with preterm labor or preterm premature rupture of membranes

Mycoplasma and Infectious Diseases in Obstetrics and Gynecology

Retrospective Analysis of Azithromycin-Resistant Ureaplasma urealyticum and Mycoplasma hominis Cervical Infection Among Pregnant Women

Prevalence and antimicrobial susceptibility of Ureaplasma urealyticum and Mycoplasma hominis in Chinese women with genital infectious diseases.

Detection of mycoplasma and chlamydia trachomatis in 159 infertility couples undergoing assisted reproductive technology

The Consequence of Infection of Ureaplasma Urealyticum in the Pregnant Women

Vaginal microbiota of pregnant women with Ureaplasma urealyticum and Mycoplasma hominis infections

Mycoplasma pulmonis genital disease: effect of rat strain on pregnancy outcome

Preconception reproductive tract infections status and adverse pregnancy outcomes: a population-based retrospective cohort study

Identification of a gene in Mycoplasma hominis associated with preterm birth and microbial burden in intraamniotic infection

Mycoplasma hominis increases the risk for Ureaplasma parvum infection in Human immunodeficiency virus infected pregnant women

Relationship between Mycoplasma genitalium and mueopurulent cervicitis

Detection rates of genital mycoplasma and other pathogens in women with acute pelvic inflammatory disease